Xi'an Zhouliang Mingkang Biopharmaceutical Technology

Xi'an Zhouliang Mingkang Biopharmaceutical Technology is a Chinese biotechnology company focused on the discovery and development of innovative small molecule therapeutics, particularly in the field of targeted protein degradation. Established in 2021 and headquartered in Xi'an, the company leverages its expertise in medicinal chemistry and structural biology to target challenging proteins involved in cancer and metabolic diseases. The firm's research efforts are centered on developing high-potency inhibitors and degraders, with a specific focus on deubiquitinating enzymes such as USP7. Zhouliang Mingkang operates primarily in the pre-clinical phase, aiming to advance its internal pipeline toward IND-enabling studies. The company represents a key player in the emerging life sciences cluster in Shaanxi Province, often collaborating with local academic institutions for translational research.